Romosozumab增加日本老年骨质疏松症患者的骨矿物质密度。

IF 1.9 4区 医学 Q3 RHEUMATOLOGY
Shohei Anno, Tadashi Okano, Yuko Sugioka, Shigeyuki Wakitani, Takahiro Iida
{"title":"Romosozumab增加日本老年骨质疏松症患者的骨矿物质密度。","authors":"Shohei Anno, Tadashi Okano, Yuko Sugioka, Shigeyuki Wakitani, Takahiro Iida","doi":"10.1093/mr/roaf054","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>This study aimed to evaluate the efficacy of romosozumab in older Japanese patients with osteoporosis.</p><p><strong>Methods: </strong>Bone mineral density (BMD) was measured at 0, 4, 6, and 12 months after romosozumab treatment.</p><p><strong>Results: </strong>Of 125 patients with osteoporosis (mean age: 77.6 ± 7.5 years), 115 completed BMD measurements at the lumbar spine, total hip, and femoral neck. The BMD at the lumbar spine (11.5%, p < 0.01), total hip (3.0%, p < 0.01), and femoral neck (3.7%, p < 0.01) increased 12 months after treatment. There were no differences in the improvement ratio of BMD after 12 months of treatment at the lumbar spine, total hip, and femoral neck among 76 patients aged ≥75 years and 39 aged < 75 years (11.0 versus 12.5%: p = 0.48, 3.0 versus 3.0%: p = 0.83, 3.6 versus 4.1%: p = 0.92), 48 with prior treatment of osteoporosis and 67 without prior treatment of osteoporosis (10.8 versus 12.1%: p = 0.56, 2.1 versus 3.7%: p = 0.25, 2.8 versus 4.5%: p = 0.61), and 55 patients with a history of fragility fracture and 60 without a history of fragility fracture (11.8 versus 11.3%: p = 0.88, 2.4 versus 3.5%: p = 0.51, 2.0 versus 5.3%: p = 0.11).</p><p><strong>Conclusions: </strong>Romosozumab improved BMD at the lumbar spine, total hip, and femoral neck in older adults with osteoporosis.</p>","PeriodicalId":18705,"journal":{"name":"Modern Rheumatology","volume":" ","pages":""},"PeriodicalIF":1.9000,"publicationDate":"2025-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Romosozumab increases bone mineral density in Japanese older adults with osteoporosis.\",\"authors\":\"Shohei Anno, Tadashi Okano, Yuko Sugioka, Shigeyuki Wakitani, Takahiro Iida\",\"doi\":\"10.1093/mr/roaf054\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>This study aimed to evaluate the efficacy of romosozumab in older Japanese patients with osteoporosis.</p><p><strong>Methods: </strong>Bone mineral density (BMD) was measured at 0, 4, 6, and 12 months after romosozumab treatment.</p><p><strong>Results: </strong>Of 125 patients with osteoporosis (mean age: 77.6 ± 7.5 years), 115 completed BMD measurements at the lumbar spine, total hip, and femoral neck. The BMD at the lumbar spine (11.5%, p < 0.01), total hip (3.0%, p < 0.01), and femoral neck (3.7%, p < 0.01) increased 12 months after treatment. There were no differences in the improvement ratio of BMD after 12 months of treatment at the lumbar spine, total hip, and femoral neck among 76 patients aged ≥75 years and 39 aged < 75 years (11.0 versus 12.5%: p = 0.48, 3.0 versus 3.0%: p = 0.83, 3.6 versus 4.1%: p = 0.92), 48 with prior treatment of osteoporosis and 67 without prior treatment of osteoporosis (10.8 versus 12.1%: p = 0.56, 2.1 versus 3.7%: p = 0.25, 2.8 versus 4.5%: p = 0.61), and 55 patients with a history of fragility fracture and 60 without a history of fragility fracture (11.8 versus 11.3%: p = 0.88, 2.4 versus 3.5%: p = 0.51, 2.0 versus 5.3%: p = 0.11).</p><p><strong>Conclusions: </strong>Romosozumab improved BMD at the lumbar spine, total hip, and femoral neck in older adults with osteoporosis.</p>\",\"PeriodicalId\":18705,\"journal\":{\"name\":\"Modern Rheumatology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2025-06-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Modern Rheumatology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1093/mr/roaf054\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"RHEUMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Modern Rheumatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/mr/roaf054","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

目的:本研究旨在评估romosozumab在日本老年骨质疏松症患者中的疗效。方法:在罗莫索单抗治疗后0、4、6和12个月测量骨密度(BMD)。结果:125例骨质疏松患者(平均年龄:77.6±7.5岁)中,115例完成了腰椎、全髋关节和股骨颈的骨密度测量。结论:Romosozumab可改善老年骨质疏松症患者腰椎、全髋关节和股骨颈的骨密度。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Romosozumab increases bone mineral density in Japanese older adults with osteoporosis.

Objectives: This study aimed to evaluate the efficacy of romosozumab in older Japanese patients with osteoporosis.

Methods: Bone mineral density (BMD) was measured at 0, 4, 6, and 12 months after romosozumab treatment.

Results: Of 125 patients with osteoporosis (mean age: 77.6 ± 7.5 years), 115 completed BMD measurements at the lumbar spine, total hip, and femoral neck. The BMD at the lumbar spine (11.5%, p < 0.01), total hip (3.0%, p < 0.01), and femoral neck (3.7%, p < 0.01) increased 12 months after treatment. There were no differences in the improvement ratio of BMD after 12 months of treatment at the lumbar spine, total hip, and femoral neck among 76 patients aged ≥75 years and 39 aged < 75 years (11.0 versus 12.5%: p = 0.48, 3.0 versus 3.0%: p = 0.83, 3.6 versus 4.1%: p = 0.92), 48 with prior treatment of osteoporosis and 67 without prior treatment of osteoporosis (10.8 versus 12.1%: p = 0.56, 2.1 versus 3.7%: p = 0.25, 2.8 versus 4.5%: p = 0.61), and 55 patients with a history of fragility fracture and 60 without a history of fragility fracture (11.8 versus 11.3%: p = 0.88, 2.4 versus 3.5%: p = 0.51, 2.0 versus 5.3%: p = 0.11).

Conclusions: Romosozumab improved BMD at the lumbar spine, total hip, and femoral neck in older adults with osteoporosis.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Modern Rheumatology
Modern Rheumatology RHEUMATOLOGY-
CiteScore
4.90
自引率
9.10%
发文量
146
审稿时长
1.5 months
期刊介绍: Modern Rheumatology publishes original papers in English on research pertinent to rheumatology and associated areas such as pathology, physiology, clinical immunology, microbiology, biochemistry, experimental animal models, pharmacology, and orthopedic surgery. Occasional reviews of topics which may be of wide interest to the readership will be accepted. In addition, concise papers of special scientific importance that represent definitive and original studies will be considered. Modern Rheumatology is currently indexed in Science Citation Index Expanded (SciSearch), Journal Citation Reports/Science Edition, PubMed/Medline, SCOPUS, EMBASE, Chemical Abstracts Service (CAS), Google Scholar, EBSCO, CSA, Academic OneFile, Current Abstracts, Elsevier Biobase, Gale, Health Reference Center Academic, OCLC, SCImago, Summon by Serial Solutions
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信